Martin Stogniew
Corporate Officer/Principal at Oncoceutics, Inc.
Profile
Martin Stogniew is currently the Chief Development Officer at Oncoceutics, Inc. He previously worked as the Executive Vice President-Scientific Affairs at Vicuron Pharmaceuticals LLC and as the Vice President-Pharmaceutical Sciences at Ceptaris Therapeutics, Inc. Dr. Stogniew obtained his undergraduate and doctorate degrees from the University of Maryland.
Martin Stogniew active positions
Companies | Position | Start |
---|---|---|
Oncoceutics, Inc.
Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 2011-12-31 |
Former positions of Martin Stogniew
Companies | Position | End |
---|---|---|
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Corporate Officer/Principal | - |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Chief Tech/Sci/R&D Officer | - |
Training of Martin Stogniew
University of Maryland | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Oncoceutics, Inc.
Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
- Stock Market
- Insiders
- Martin Stogniew